LI-COR Biosciences Establishes Translational Research Group
June 9, 2010, Lincoln, NE: LI-COR® Biosciences announces the establishment of a new Translational Research group to facilitate the use of its IRDye 800CW labeled imaging agents in clinical studies for detection of disease, its progression, and for monitoring treatment and drug efficacy. IRDye 800CW has been conjugated to a variety of preclinical targeting agents by leading molecular imaging laboratories developing translatable agents. Unlike the clinically approved form of indocyanine green (ICG, Cardiogreen®), which cannot be attached to biomolecules, IRDye 800CW reactive dyes are easily conjugated to targeting agents.
An important part of the clinical translation process is production of cGMP-compliant material. LI-COR will soon be able to provide IRDye 800CW produced under cGMP at a scale suitable for smooth transition to clinical studies.
A safety and toxicity study of IRDye® 800CW entitled, "Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats," was recently published in the April 2010 issue of Molecular Imaging and Biology. The study reported no pathological evidence of toxicity based on the hematologic, clinical chemistry, and histopathologic analyses performed, making IRDye 800CW a promising label for researcher hoping to translate their imaging applications to the clinic.
"We are excited to make IRDye 800CW widely available for development of targeted probes for clinical molecular imaging," says D. Michael Olive, PhD, newly appointed vice president of translational research. "One of the most promising areas will be targeted tumor agents that will paint tumor cells for easier identification and removal by surgeons."
Olive adds that LI-COR is currently working with a growing list of collaborators who are developing new clinical imaging applications. For more information click here.